Neutrophil-lymphocyte ratio as prognostic factor in metastatic breast cancer.

Authors

Gustavo Motta Cabello Dos Santos, Nereida Kilza Costa-Lima, Isabela da Mata Tiezzi, Giovana Kobayashi Pavão, Israel Geraldo Silva, Priscila Malara Maia, Hélio Humberto Angotti Carrara, Daniel Guimarães Tiezzi

Published in

Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia. Volume 48. Epub May 12, 2026.

Abstract

The aim of the study was to analyze the role of the neutrophil to lymphocyte ratio (NLR) as a prognostic factor in metastatic breast cancer (MBC).
A retrospective cohort study including 359 recurrent MBC patients was performed. Clinical and pathological attributes were retrieved from patients' medical files and their importance in the overall survival were evaluated using the Cox univariate and multivariate proportional hazard models. A confidence interval of 95% was used to select significant variables and the Wald test was used to infer the best NLR cutoff value to discriminate into low and high categories.
In univariate analyses, the variables estrogen receptor (ER) and progesterone receptor (PR) expressions, previous treatment with adjuvant chemo, NLR, PLR (platelet-lymphocyte ratio), age at diagnosis and the main metastatic site (bone/lymph node, visceral or central nervous system) variables were significant to determine the hazards. After filtering the collinear variables, the final model was tested with 6 variables based on 339 patients and the NLR at the time of the recurrence diagnosis (NLR_rec), the hormone receptor (ER or PR) status and the age at diagnosis were considered significant. The best NLR_rec value to discriminate against patients was 4.43 (Wald test= 51.7) and there were 239 patients categorized as low and 111 as high NLR category. The median overall survival time was 18 and 4 months in NLR-low and NLR-high groups, respectively (p< 0.001).
NLR is an independent prognostic factor in recurrent MBC patients.

PMID:
42598663
Bibliographic data and abstract were imported from PubMed on 14 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.